Abstract
Introduction: To date, there is no permanent medical treatment for nasal polyposis and loss of sense of smell. Mepolizumab is an anti-IL-5 monoclonal antibody approved for the treatment of patients with eosinophilic asthma. It has been suggested that it is capable of improving olfactory dysfunction in patients with chronic rhinosinusitis and nasal polyposis.
Case: We present a 35-year-old Emirati male with progressively worsening rhinosinusitis, recurring nasal polyps and total loss of sense of smell. He was treated with oral steroids, normal saline nasal sprays and all available topical steroids without significant or permanent symptom relief. He was commenced on Mepolizumab, and upon receiving the 4th dose, he reported full recovery of his sense of smell.
Conclusion: Mepolizumab appears to be very effective in treating loss of sense of smell. Further studies should be conducted to assess the efficacy and effectiveness of Mepolizumab in patients with chronic rhinosinusitis, nasal polyposis and anosmia.
Keywords: Mepolizumab, Nasal polyps, Olfaction disorders, Sinusitis, Paranasal sinus diseases, Rhinosinusitis.
New Emirates Medical Journal
Title:Recovery of Sense of Smell by Mepolizumab in a Patient with Chronic Rhinosinusitis and Nasal Polyposis
Volume: 1
Author(s): Mohamed Abuzakouk*, Omar Ghorab, Safieeldin Ghazala and Anastasios Hantzakos
Affiliation:
- Department of Allergy and Immunology, Cleveland Clinic Abu Dhabi, Abu Dhabi,United Arab Emirates
Keywords: Mepolizumab, Nasal polyps, Olfaction disorders, Sinusitis, Paranasal sinus diseases, Rhinosinusitis.
Abstract:
Introduction: To date, there is no permanent medical treatment for nasal polyposis and loss of sense of smell. Mepolizumab is an anti-IL-5 monoclonal antibody approved for the treatment of patients with eosinophilic asthma. It has been suggested that it is capable of improving olfactory dysfunction in patients with chronic rhinosinusitis and nasal polyposis.
Case: We present a 35-year-old Emirati male with progressively worsening rhinosinusitis, recurring nasal polyps and total loss of sense of smell. He was treated with oral steroids, normal saline nasal sprays and all available topical steroids without significant or permanent symptom relief. He was commenced on Mepolizumab, and upon receiving the 4th dose, he reported full recovery of his sense of smell.
Conclusion: Mepolizumab appears to be very effective in treating loss of sense of smell. Further studies should be conducted to assess the efficacy and effectiveness of Mepolizumab in patients with chronic rhinosinusitis, nasal polyposis and anosmia.
Export Options
About this article
Cite this article as:
Abuzakouk Mohamed *, Ghorab Omar , Ghazala Safieeldin and Hantzakos Anastasios , Recovery of Sense of Smell by Mepolizumab in a Patient with Chronic Rhinosinusitis and Nasal Polyposis, New Emirates Medical Journal 2020; 1 (2) . https://dx.doi.org/10.2174/0250688202002022006
DOI https://dx.doi.org/10.2174/0250688202002022006 |
Print ISSN 0250-6882 |
Publisher Name Bentham Science Publisher |
Online ISSN 0250-6882 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Possible Approach for Stem Cell Gene Therapy of Fanconi Anemia
Current Gene Therapy Design and Development of Nanoemulsion Systems Containing Interferon Gamma
Protein & Peptide Letters BX471: A CCR1 Antagonist with Anti-Inflammatory Activity in Man
Mini-Reviews in Medicinal Chemistry The Cyclodextrin Sugammadex and Anaphylaxis to Rocuronium: Is Rocuronium Still Potentially Allergenic in the Inclusion Complex Form?
Mini-Reviews in Medicinal Chemistry Thalidomide as an Immunotherapeutic Agent: The Effects on Neutrophil- Mediated Inflammation
Current Pharmaceutical Design Epigenetic Regulation of Epithelial to Mesenchymal Transition
Current Cancer Drug Targets Nanocarriers Based Anticancer Drugs: Current Scenario and Future Perceptions
Current Drug Targets Mast Cells as Targets of Pimecrolimus
Current Pharmaceutical Design Pomegranate Extracts and Cancer Prevention: Molecular and Cellular Activities
Anti-Cancer Agents in Medicinal Chemistry The Role of Phospholipase A2 and Lipoxygenases Associated with Arachidonic Acid in Oxidative Stress-Induced Cell Injury
Current Enzyme Inhibition Erythropoietin: New Approaches to Improved Molecular Designs and Therapeutic Alternatives
Current Pharmaceutical Design Pharmacological Activation of Protein Phosphatase 2 A (PP2A): A Novel Strategy to Fight Against Human Malignancies?
Current Medicinal Chemistry MicroRNAs: Key Players in Microglia and Astrocyte Mediated Inflammation in CNS Pathologies
Current Medicinal Chemistry Nanocrystalline ZnO: A Competent and Reusable Catalyst for the Preparation of Pharmacology Relevant Heterocycles in the Aqueous Medium
Current Green Chemistry Inhibitors of ER Aminopeptidase 1 and 2: From Design to Clinical Application
Current Medicinal Chemistry A Stress Repair Mechanism That Maintains Vertebrate Structure During Stress
Cardiovascular & Hematological Disorders-Drug Targets Synthesis and Biological Evaluation of a Series of 4-(arylamido/imidoalkyl)- 5-(arylideno- 4-oxo-2-thio-imidazolidinyl)-N-(methyl-phenyl-imino) Acridinium Iodides as Potential Antiviral Agents
Letters in Drug Design & Discovery Heat Shock Proteins And Neuroprotection
Recent Patents on DNA & Gene Sequences Lipoxygenase Inhibitors as Cancer Chemopreventives: Discovery, Recent Developments and Future Perspectives
Current Medicinal Chemistry Delivery Systems for Biopharmaceuticals. Part I: Nanoparticles and Microparticles
Current Pharmaceutical Biotechnology